ClinicalTrials.Veeva

Menu

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

Organon logo

Organon

Status and phase

Completed
Phase 3

Conditions

Benign Prostatic Hyperplasia

Treatments

Drug: Comparator: placebo / Duration of Treatment: 48 weeks
Drug: MK0906, finasteride / Duration of Treatment: 48 weeks

Study type

Interventional

Funder types

Industry

Identifiers

NCT00127179
0906-140
MK0906-140
2005_042

Details and patient eligibility

About

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Enrollment

600 patients

Sex

Male

Ages

50 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with benign prostatic hyperplasia

Exclusion criteria

  • Patients who are suspected to be suffering from prostatic cancer

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems